{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:23:47Z","timestamp":1791181427112,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.nano.2012.05.012","type":"journal-article","created":{"date-parts":[[2012,5,31]],"date-time":"2012-05-31T00:01:07Z","timestamp":1338422467000},"page":"28-38","source":"Crossref","is-referenced-by-count":45,"title":["Nanomedicine applications towards the cure of HIV"],"prefix":"10.1016","volume":"9","author":[{"given":"Julianna","family":"Lisziewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enik\u0151 R.","family":"T\u0151ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2012.05.012_bb0005","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.nano.2012.05.012_bb0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.3399881","article-title":"HIV causes AIDS","volume":"241","author":"Blattner","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.nano.2012.05.012_bb0015","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1126\/science.1078050","article-title":"Historical essay. The early years of HIV\/AIDS","volume":"298","author":"Gallo","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nano.2012.05.012_bb0020","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMp038194","article-title":"The discovery of HIV as the cause of AIDS","volume":"394","author":"Gallo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2012.05.012_bb0025","unstructured":"UNAIDS Report on the Global AIDS Epidemic 2010. http:\/\/www.unaids.org\/globalreport\/Global_report.htm."},{"key":"10.1016\/j.nano.2012.05.012_bb0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced Human Immunodeficiency Virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nano.2012.05.012_bb0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1258\/095646205774988109","article-title":"Causes of the decline in AIDS deaths, United States, 1995-2002: Prevention, treatment or both?","volume":"16","author":"Holtgrave","year":"2005","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.nano.2012.05.012_bb0040","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1086\/644772","article-title":"Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy","volume":"49","author":"Losina","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nano.2012.05.012_bb0045","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/QAD.0b013e3282f7cb76","article-title":"CD4+ count and risk of NON-AIDS diseases following initial treatment for HIV infection","volume":"22","author":"Baker","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.nano.2012.05.012_bb0050","doi-asserted-by":"crossref","first-page":"e7658","DOI":"10.1371\/journal.pone.0007658","article-title":"HIV-1 residual viremia correlates with persisitent T-cell activation in poor immunological responders to combination antiretroviral therapy","volume":"4","author":"Mavigner","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2012.05.012_bb0055","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1128\/JVI.75.14.6508-6516.2001","article-title":"Picker LJ and Koup RA Decay kinetics of Human Immunodeficiency Virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy","volume":"75","author":"Casazza","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2012.05.012_bb0060","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","article-title":"Evidence for the cure of HIV infection by CCR5D32\/D32 stem cell transplantation","volume":"117","author":"Allers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nano.2012.05.012_bb0065","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1056\/NEJM199905273402114","article-title":"Control of HIV despite the discontinuation of antiretroviral therapy","volume":"340","author":"Lisziewicz","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nano.2012.05.012_bb0070","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","article-title":"Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy","volume":"27","author":"Deeks","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.nano.2012.05.012_bb0075","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/infdis\/jiq138","article-title":"A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response","volume":"203","author":"Hatano","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nano.2012.05.012_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-Specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.nano.2012.05.012_bb0085","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/17425247.3.5.613","article-title":"Nanoparticulate drug carriers for delivery of HIV\/AIDS therapy to viral reservoir sites","volume":"3","author":"Vyas","year":"2006","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.nano.2012.05.012_bb0090","first-page":"157","article-title":"Role of nanotechnology in HIV\/AIDS treatment: potential to overcome the viral reservoir challenge","volume":"6","author":"Amiji","year":"2006","journal-title":"Discov Med"},{"key":"10.1016\/j.nano.2012.05.012_bb0095","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2217\/nnm.09.38","article-title":"NanoART, neuroAIDS and CNS drug delivery","volume":"4","author":"Nowacek","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2012.05.012_bb0100","doi-asserted-by":"crossref","first-page":"e18270","DOI":"10.1371\/journal.pone.0018270","article-title":"Activation of latent HIV using drug-loaded nanoparticles","volume":"6","author":"Kovochich","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2012.05.012_bb0105","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jps.21020","article-title":"pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to enatrap a solute","volume":"97","author":"Choi","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nano.2012.05.012_bb0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00126334-200312010-00005","article-title":"Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study i HIV-2287-infected macaques","volume":"34","author":"Kinman","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.nano.2012.05.012_bb0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1208\/s12248-010-9187-z","article-title":"AIDS treatment and novel anti-HIV compounds improved by nanotechnology","volume":"12","author":"Ma","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.nano.2012.05.012_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2217\/nnm.09.90","article-title":"Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailabilty","volume":"5","author":"Chiappetta","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2012.05.012_bb0125","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","article-title":"Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment","volume":"72","author":"Baert","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nano.2012.05.012_bb0130","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.nano.2012.05.012_bb0135","unstructured":"NIH Discontinues Tenofovir Vaginal Gel in \u02bbVOICE' HIV Prevention Study. http:\/\/www.nih.gov\/news\/health\/nov2011\/niaid-25.htm."},{"key":"10.1016\/j.nano.2012.05.012_bb0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2012.05.012_bb0145","first-page":"389","article-title":"Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?","volume":"3","author":"Das Neves","year":"2011","journal-title":"John Wiley and Sons Inc"},{"key":"10.1016\/j.nano.2012.05.012_bb0150","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/03639040601050163","article-title":"Development and in vitro evaluation of surface modified poly (lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine","volume":"33","author":"Grabovac","year":"2007","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.nano.2012.05.012_bb0155","doi-asserted-by":"crossref","first-page":"e21547","DOI":"10.1371\/journal.pone.0021547","article-title":"Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2012.05.012_bb0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/aid.2006.0076","article-title":"Evaluation of -2 RANTES vaginal microbicide formulations in a nonhuman primate simian\/human immunodeficiency virus (SHIV) challenge model","volume":"23","author":"Kish-Catalone","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.nano.2012.05.012_bb0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.virol.2010.06.008","article-title":"Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV","volume":"405","author":"Caron","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.nano.2012.05.012_bb0170","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1021\/nn9018587","article-title":"Stimuli-responsive liposome fusion mediated by gold nanoparticles","volume":"4","author":"Pornpattananangkul","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2012.05.012_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-3155-8-1","article-title":"PVP-coated silver nanoparticles block the transmission of cel.l-free and cell-associated HIV-1 in human cervical culture","volume":"8","author":"Lara","year":"2010","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nano.2012.05.012_bb0180","first-page":"1806","article-title":"Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 transinfection of human T cells","volume":"10","author":"Martinez-Avila","year":"2009","journal-title":"Chem Biochem"},{"key":"10.1016\/j.nano.2012.05.012_bb0185","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/nnm.10.1","article-title":"Emerging nanotechnology approaches for HIV\/AIDS treatment and prevention","volume":"5","author":"Mamo","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2012.05.012_bb0190","first-page":"561","article-title":"VivaGel (SPL 7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection","volume":"2","author":"Rupp","year":"2007","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.nano.2012.05.012_bb0195","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1128\/JVI.75.19.9037-9043.2001","article-title":"Induction of potent immune responses by cationic microparticles with adsorbed Human Immunodeficiency Virus DNA vaccines","volume":"75","author":"O'Hagan","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2012.05.012_bb0200","unstructured":"Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00073216?term=PLG+HIV&rank=1."},{"key":"10.1016\/j.nano.2012.05.012_bb0205","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/infdis\/jiq175","article-title":"A Trimeric, V2-DELETED HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers","volume":"203","author":"Spearman","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nano.2012.05.012_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymeth.2006.05.016","article-title":"Pathogen recognition and development of particulate vaccines: Does size matter?","volume":"40","author":"Xiang","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.nano.2012.05.012_bb0215","doi-asserted-by":"crossref","DOI":"10.1515\/EJNM.2010.3.1.13","article-title":"The Janus face of immune stimulation by nanomedicines examples for the good and the bad","author":"Lisziewicz","year":"2010","journal-title":"Eur J Nanomed"},{"key":"10.1016\/j.nano.2012.05.012_bb0220","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-75-9-2271","article-title":"Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies","volume":"75","author":"Christensen","year":"1994","journal-title":"J Gen Virol"},{"key":"10.1016\/j.nano.2012.05.012_bb0225","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection - A randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.nano.2012.05.012_bb0230","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/00002030-199310000-00003","article-title":"Immunization of human HIV-seronegative volunteers with recombinant p17\/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses","volume":"7","author":"Martin","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.nano.2012.05.012_bb0235","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.addr.2007.05.017","article-title":"Nanotechnology in vaccine delivery","volume":"60","author":"Peek","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2012.05.012_bb0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2006.07.006","article-title":"Coadsorption of HIV-1 P24 and GP120 Proteins to surfactant-free anionic PLA Nanoparticles preserves antigenicity and immunogenicity","volume":"115","author":"Lamalle-Bernard","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2012.05.012_bb0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4161\/hv.5.3.6589","article-title":"Enhanced in VIVO Immunogenicity of SIV Vaccine Candidates with cationic liposome-DNA Complexes In a Rhesus macaque Pilot Study","volume":"5","author":"Fairman","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.nano.2012.05.012_bb0250","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2012.05.012_bb0255","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.1074\/jbc.274.27.19087","article-title":"Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cell","volume":"274","author":"Diebold","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nano.2012.05.012_bb0260","series-title":"Rational design of formulated DNA vaccines: the DermaVir approach, in gene vaccines","first-page":"109","author":"Natz","year":"2011"},{"key":"10.1016\/j.nano.2012.05.012_bb0265","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11051-009-9632-z","article-title":"In quest of a systematic framework for unifying and defining nanoscience","volume":"11","author":"Tomalia","year":"2009","journal-title":"J Nanopart Res"},{"key":"10.1016\/j.nano.2012.05.012_bb0270","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2010.11.019","article-title":"A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV","volume":"29","author":"Somogyi","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2012.05.012_bb0275","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijpharm.2010.03.048","article-title":"Rational development of a stable liquid formulation for nanomedicine products","volume":"392","author":"Toke","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2012.05.012_bb0280","article-title":"Structure and biological activity of pathogen-like synthetic nanomedicines","author":"Lorincz","year":"2011","journal-title":"Nanomedicine: NMB"},{"key":"10.1016\/j.nano.2012.05.012_bb0285","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature09385","article-title":"Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation","volume":"467","author":"Mouquet","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.nano.2012.05.012_bb0290","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.it.2006.10.005","article-title":"Targeting dendritic cells with biomaterials: developing the next generation of vaccines","volume":"27","author":"Reddy","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1016\/j.nano.2012.05.012_bb0295","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G","article-title":"Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery","volume":"67","author":"Schaffer","year":"2000","journal-title":"Biotech Bioeng"},{"key":"10.1016\/j.nano.2012.05.012_bb0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10616-009-9215-y","article-title":"The heterogeneous nature of polyethylenimine-DNA complex formation affects transient gene expression","volume":"60","author":"Han","year":"2009","journal-title":"Cytotechnology"},{"key":"10.1016\/j.nano.2012.05.012_bb0305","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1073\/pnas.0636277100","article-title":"Efficient active transport of gene nanocarriers to the nucleus","volume":"100","author":"Suh","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.nano.2012.05.012_bb0310","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nano.2012.05.012_bb0315","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1586\/14760584.7.8.1201","article-title":"Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice","volume":"7","author":"Nicolas","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.nano.2012.05.012_bb0320","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1523-1747.2001.01247.x","article-title":"A strikingly constant ratio exists between Langerhans cells and other epidermal cells in human skin. A stereologic study using the optical disector method and the confocal laser scanning microscope","volume":"116","author":"Bauer","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.nano.2012.05.012_bb0325","doi-asserted-by":"crossref","first-page":"7621","DOI":"10.1128\/JVI.75.16.7621-7628.2001","article-title":"Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells","volume":"75","author":"Lisziewicz","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2012.05.012_bb0330","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.0022-202X.2004.23535.x","article-title":"DermaVir: a novel topical vaccine for HIV\/AIDS","volume":"124","author":"Lisziewicz","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.nano.2012.05.012_bb0335","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002030-200501030-00004","article-title":"Control of viral rebound through therapeutic immunization with DermaVir","volume":"19","author":"Lisziewicz","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.nano.2012.05.012_bb0340","doi-asserted-by":"crossref","first-page":"e35416","DOI":"10.1371\/journal.pone.0035416","article-title":"Single DermaVir immunization: dose-dependent expansion of precursor\/memory T cells against all HIV antigens in HIV-1 infected individuals","volume":"7","author":"Lisziewicz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2012.05.012_bb0345","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.4049\/jimmunol.180.9.5907","article-title":"HIV-1-Specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals","volume":"180","author":"Calarota","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2012.05.012_bb0350","unstructured":"Rodriguez B, Asmuth D, Matining R, Spritzler J, Li X, et al. Repeated-dose transdermal administration of DermaVir, a candidate plasmid DNA-based therapeutic HIV vaccine, is safe and well-tolerated: a 61-week analysis of ACTG Study 5176, paper presented at XVIIIth International AIDS Conference, 2010, Vienna, Austria, Abstract # A-240-0111-10145."},{"key":"10.1016\/j.nano.2012.05.012_bb0355","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nano.2012.05.012_bb0360","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nri1706","article-title":"Perils at mucosal front lines for HIV and SIV and their hosts","volume":"5","author":"Haase","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nano.2012.05.012_bb0365","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaci.2008.05.033","article-title":"Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection","volume":"122","author":"Shen","year":"2008","journal-title":"J Allergy Clin Immun"},{"key":"10.1016\/j.nano.2012.05.012_bb0370","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy","volume":"106","author":"Dinosoa","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2012.05.012_bb0375","first-page":"1","article-title":"The effect of Raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial","volume":"7","author":"Gandhi","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.nano.2012.05.012_bb0380","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/650749","article-title":"Short-course Raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy","volume":"50","author":"McMahon","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nano.2012.05.012_bb0385","unstructured":"DermaVir Search Results. http:\/\/www.clinicaltrials.gov\/ct2\/results?term=dermavir. Accessed 12 January 2012."},{"key":"10.1016\/j.nano.2012.05.012_bb0390","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymeth.2006.05.022","article-title":"Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases","volume":"40","author":"Fuller","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.nano.2012.05.012_bb0395","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1016\/j.vaccine.2009.05.028","article-title":"Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination","volume":"27","author":"Aline","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2012.05.012_bb0400","doi-asserted-by":"crossref","first-page":"E29231","DOI":"10.1371\/journal.pone.0029231","article-title":"Safety and immunogenicity of AN HIV-1 GAG DNA vaccine with or without il-12 and\/or il-15 plasmid cytokine adjuvant in healthy, hiv-1 uninfected adults","volume":"7","author":"Kalams","year":"2012","journal-title":"PLoS One"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963412002870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963412002870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T03:52:30Z","timestamp":1542945150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963412002870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1549963412002870"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2012.05.012","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}